Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2014 08/18/2014 08/19/2014 08/20/2014 08/21/2014 Date
67.26(c) 67.22(c) 68.05(c) 67.33(c) 65.36(c) Last
564 097 608 243 392 567 487 580 653 746 Volume
+0.43% -0.06% +1.23% -1.06% -2.93% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference. It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 34,1 M
EBIT 2014 -314 M
Net income 2014 -334 M
Finance 2014 737 M
Yield 2014 -
Sales 2015 49,6 M
EBIT 2015 -192 M
Net income 2015 -209 M
Finance 2015 698 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 125x
EV / Sales 2015 86,5x
Capitalization 4 991 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
2d ago ALNYLAM PHARMACEUTICALS : Receives Notice of Allowance from United States Patent..
3d ago ALNYLAM PHARMACEUTICALS : Updates on Second Quarter Results
08/14 ALNYLAM PHARMACEUTICALS : Posts Second Quarter Results
08/13 MEDICINES : and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCS..
08/13 ALNYLAM PHARMACEUTICALS : Receives Orphan Drug Designations in the European Unio..
08/08 ALNYLAM PHARMACEUTICALS : Assigned Patent
08/07 ALNYLAM PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
08/07 ALNYLAM PHARMACEUTICALS : Reports Second Quarter 2014 Financial Results and High..
08/07 ALNYLAM PHARMACEUTICALS : Receives Orphan Drug Designations in the European Unio..
08/07 ALNYLAM PHARMACEUTICALS : Introduces 3 Events to Its 'RNAi Roundtable' Webcast S..
08/01 ALNYLAM PHARMACEUTICALS : Assigned Patent
08/01 ALNYLAM PHARMACEUTICALS : Adds 3 Events to Its 'RNAi Roundtable' Webcast Series
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
Alnylam Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Alnylam Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF